{"id":"generic-bupropion","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Insomnia"},{"rate":"17-24","effect":"Dry mouth"},{"rate":"13-18","effect":"Nausea"},{"rate":"22-26","effect":"Headache"},{"rate":"6-11","effect":"Dizziness"},{"rate":"0.4","effect":"Seizures"},{"rate":"2-3","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the reuptake of norepinephrine and dopamine, bupropion increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their signaling. Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion does not significantly affect serotonin reuptake. This mechanism makes it particularly useful for depression with anhedonia or fatigue, and for smoking cessation where dopamine's role in reward and motivation is therapeutically relevant.","oneSentence":"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:03.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Seasonal affective disorder"},{"name":"Smoking cessation (nicotine dependence)"}]},"trialDetails":[{"nctId":"NCT06809166","phase":"PHASE4","title":"Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","status":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-07-04","conditions":"Obesity, Weight Loss, Weight Management","enrollment":40},{"nctId":"NCT04709094","phase":"PHASE1","title":"A Drug Interaction Study of Danicopan","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-07-28","conditions":"Healthy","enrollment":52},{"nctId":"NCT02209597","phase":"PHASE4","title":"Clinical Study of Generic and Brand Bupropion in Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-06-25","conditions":"Major Depressive Disorder","enrollment":74},{"nctId":"NCT02078180","phase":"PHASE4","title":"Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2014-04","conditions":"Depression","enrollment":34},{"nctId":"NCT01156610","phase":"NA","title":"Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-11","conditions":"Smoking, Smoking Cessation","enrollment":706},{"nctId":"NCT00930306","phase":"PHASE1","title":"AZD2066 Cocktail Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Chronic Pain","enrollment":15}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"COMPLETED SUICIDE"},{"count":3,"reaction":"EXPOSURE VIA INGESTION"},{"count":3,"reaction":"OVERDOSE"},{"count":3,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":2,"reaction":"AGITATION"},{"count":2,"reaction":"CARDIO-RESPIRATORY ARREST"},{"count":2,"reaction":"DRUG ABUSE"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"DYSGEUSIA"},{"count":2,"reaction":"NERVOUSNESS"}],"_approvalHistory":[],"publicationCount":1863,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Wellbutrin"],"phase":"marketed","status":"active","brandName":"generic bupropion","genericName":"generic bupropion","companyName":"University of Michigan","companyId":"university-of-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that increases levels of norepinephrine and dopamine in the brain by blocking their reuptake at the presynaptic neuron. Used for Major depressive disorder, Seasonal affective disorder, Smoking cessation (nicotine dependence).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}